NAD+ buying guide
Does NAD+ help with weight loss? No trial of NAD+ itself has measured it
There’s no human evidence that NAD+ itself helps with weight loss: no published trial has given people NAD+ and measured their weight. The nearest evidence comes from supplements that raise it, where one 28-day trial of 30 adults found 1.9 kg more weight lost than placebo and two trials of nicotinamide riboside found no effect on body composition, or only a minor one.
No trial has given people NAD+ for weight
Nobody has tested it. Five human trials in PubMed carry NAD+ in the title and weight or obesity in the abstract, and not one of them gave people NAD+ itself.
| What was counted | Out of 5 trial records returned |
|---|---|
| Gave people NAD+ itself | 0 |
| Gave people an NAD+ precursor (NMN) | 2 |
| Tested exercise, a weight-loss program or an unrelated drug | 3 |
| The same search with aspirin in the title | 43 |
Both NMN records gave people MIB-626, a pharmaceutical NMN, and one of them is the 28-day trial read below.
Source: PubMed, searched September 2026: NAD+, NAD or nicotinamide adenine dinucleotide in the title, with weight loss, obesity, overweight, body weight or adiposity in the title or abstract, limited to human trials. The same search with aspirin in the title returns 43 records.
The widest review of the field lands in the same place. A 2026 systematic review of NAD+ supplementation gathered 33 human intervention studies and reported that “No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications.”
What the precursor trials found
What does exist is a short run of trials of precursors, the molecules the body turns into NAD+, in people carrying extra weight. They aren’t NAD+ and they aren’t sold the same way; how the precursors differ from NAD+ itself, and what each costs, is its own page.
| Trial | Who took what, for how long | What happened to weight |
|---|---|---|
| Am J Clin Nutr 2018 | 40 men with obesity; nicotinamide riboside, 1,000 mg twice a day, for 12 weeks | No effect on body composition |
| Am J Clin Nutr 2020 | 13 overweight or obese adults; nicotinamide riboside, 1,000 mg a day, 6 weeks on each arm of a crossover | Fat-free mass 62.65% of the body against 61.32% on placebo, which the authors call a minor change |
| J Clin Endocrinol Metab 2023 | 30 overweight or obese adults aged 45 and over; pharmaceutical NMN (MIB-626), two 500 mg tablets twice a day, for 28 days | 1.9 kg more lost than on placebo |
| Front Nutr 2023, a meta-analysis | 22 treatment arms, 5,144 people; nicotinic acid or nicotinamide, not nicotinamide riboside or NMN | BMI down 0.19 kg/m²; no significant effect on body weight |
Not one of these gave anyone NAD+ itself. They are the evidence that exists, and it is about the molecules a body turns into NAD+.
Source: Am J Clin Nutr 2018, PMID 29992272; Am J Clin Nutr 2020, PMID 32320006; J Clin Endocrinol Metab 2023, PMID 36740954; Front Nutr 2023, PMID 37854354. Each row says what that paper’s own abstract says. Documents read in September 2026.
The two nicotinamide riboside trials are the cleanest test, and neither found much. In 40 men with obesity, 12 weeks at 2,000 mg a day “had no effect on resting energy expenditure, lipolysis, oxidation of lipids, or body composition.” In a crossover of 13 adults, six weeks at 1,000 mg a day raised fat-free mass by 1.34 percentage points, which the authors call “minor changes in body composition”, and “no other metabolic health effects were observed”.
The meta-analysis in the last row is about other molecules, nicotinic acid and nicotinamide. Its pooled result was a BMI 0.19 kg/m² lower, and “no significant effect was observed on body weight and leptin”. The BMI drop was larger with nicotinic acid, the form of vitamin B3 that causes the niacin flush.
The one trial that moved the scale
The positive result is a 2023 trial of MIB-626, an investigational drug formulation of NMN from Metro International Biotech. Thirty overweight or obese adults aged 45 and over were randomized, two to one, to two 500 mg tablets twice a day or to placebo, for 28 days.
“Body weight (difference -1.9 [-3.3, -0.5] kg, P = .008)”
Journal of Clinical Endocrinology and Metabolism, 2023, PMID 36740954. Randomized and placebo-controlled, 28 days.
That’s 1.9 kg more lost on the tablets than on placebo, with a confidence interval running from 0.5 to 3.3 kg. Diastolic blood pressure and cholesterol also fell further on the drug. Liver and abdominal fat didn’t move: “Insulin sensitivity and hepatic and intra-abdominal fat did not change in either group.” Strength, how quickly muscles tired, aerobic capacity and stair-climbing power didn’t differ between the groups.
Read it for what it is. Thirty people, four weeks, an investigational tablet rather than a shelf supplement, and authors who write that the data “provide the rationale for larger trials”. It’s a signal worth testing, and it isn’t a result for NAD+ itself.
Losing weight changes the NAD+ pathway
The evidence in people runs more clearly the other way. In 26 pairs of identical twins who differed in weight, the heavier twin’s fat tissue showed lower expression of the sirtuin genes and of the genes that build NAD+, and a trend toward more activity from PARP, the enzyme that uses NAD+ up.
A year-long weight-loss program ran the same comparison forward. Nineteen people with obesity lost an average of 11.7% of their weight in the first five months, and in their fat tissue the expression of SIRT1 rose, along with NAMPT, the gene that limits how fast NAD+ is made. In those who kept losing, SIRT1 kept climbing. In those who regained, it fell back to where it started.
Both studies measured genes and enzymes in fat, not NAD+ itself, and neither proves cause. What they show is weight loss moving the NAD+ machinery. The case that pushing NAD+ up makes weight come off rests, so far, on one four-week trial. What does raise NAD+ in people, and where it was measured, is a separate page.
Why NAD+ shows up in weight-loss plans
Because some sellers package it with weight-loss drugs. In this index, 2 sellers name a GLP-1 drug in the sentence printed around its NAD+ price. Each excerpt keeps its own source date:
- ClickSlim: “Pricing: $249/month or $199 with GLP1” Read September 2026.
- HelloWellness: “SEMAGLUTIDE & NAD+ 3 MONTH PLAN $598 every 3 months” Read September 2026.
In a plan like that, NAD+ rides alongside a GLP-1 drug, and the price can’t tell you which ingredient a result would come from. It can’t tell you what the NAD+ costs, either: 2 of those 4 figures are bundle prices that can’t be split, and they are kept here with no NAD+ amount at all.
Priced on its own, NAD+ is a different comparison. The sellers that publish a standing monthly rate are laid out one by one on the NAD+ price index, and every seller’s figures are on its review page.
The trial nobody has run
A trial of NAD+ itself, against placebo, with weight named as the outcome before it starts. Until one exists, these stay open.
Does NAD+ itself, injected or taken any other way, cause weight loss? No trial has given it to people and measured their weight.
A randomized, placebo-controlled human trial of NAD+ itself with body weight or fat mass as a stated endpoint. The only weight results in people come from precursors: one 28-day trial of 30 adults on a pharmaceutical NMN, and two trials of nicotinamide riboside that found no effect on body composition, or a minor one.
Does raising NAD+ make anyone healthier? Supplements raise the blood number reliably; whether that changes an outcome a person would notice has not been shown consistently in trials.
Larger, longer randomized trials with a clinical endpoint named in advance. A 2026 systematic review of 33 human intervention studies found the outcome results heterogeneous and often null, and found no outcome trial at all of NAD+ given by vein or by intramuscular injection.
Read next
About this page
Nothing here is medical advice, diagnosis or treatment. This is a price index, and pages like this one exist because a reader cannot judge a price without knowing what the thing is. Talk to a licensed clinician before starting or stopping anything, and see the medical disclaimer.
Document sources read September 2026. The references below retain each source reading date and the date printed on the document itself. An editorial revision does not refresh those source records. If something here is wrong, the corrections page says how that gets fixed and what has been fixed before.
Sources
- NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
- Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.
- A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
- Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
- The effects of NAD+ precursor (nicotinic acid and nicotinamide) supplementation on weight loss and related hormones: a systematic review and meta-regression analysis of randomized controlled trials.
- Niacin — Health Professional Fact Sheet
- MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults.
- Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins.
- Weight Loss Is Associated With Increased NAD(+)/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue.